WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK) (known as MSD outside the United States and Canada) today announced that the U.S. Food and Drug Administration (FDA) has approved SYLATRON ...
Helix BioPharma announces positive phase II clinical results with its Topical Interferon Alpha-2b AURORA, ON, March 30 - Helix BioPharma Corp. Helix today announced positive results from its phase II ...
The COMBI study, a prospective, open‐label, single‐arm phase 2 study ongoing in Denmark, is investigating the feasibility of treating patients with low- to intermediate-risk myelofibrosis ...
Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging PURPOSE: The efficacy of interferon alfa has been ...
A chemically modified (pegylated*) form of interferon alfa-2b improves recurrence-free survival (RFS) in melanoma patients compared with observation alone, conclude authors of an Article in this ...
To share our initial experience in the use of intralesional interferon alpha-2a at primary presentation in ocular surface tumours as a method of immunoreduction prior to definitive surgical management ...
Please provide your email address to receive an email when new articles are posted on . 38% of patients with cutaneous lupus erythematosus displayed evidence of positive interferon (IFN)-alpha ...
Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. Thirty-five patients (25 with cholangiocarcinoma and 10 with gallbladder carcinoma) were registered onto this phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback